Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%
Aug 11
Have your own idea? Try our Stock Screener
U.S. Life Sciences Industry Analysis
UpdatedAug 13, 2025
DataAggregated Company Financials
Companies64
- 7D2.4%
- 3M12.6%
- 1Y-21.2%
- YTD-11.5%
Over the last 7 days, the Life Sciences industry has risen 2.4%, driven by gains in Danaher and Thermo Fisher Scientific of 3.4% and 2.4%, respectively. During this same period, the Charles River Laboratories International underperformed, falling 8.8%. In the past year, the industry is down 21%. Looking forward, earnings are forecast to grow by 13% annually.
Industry Valuation and Performance
Has the U.S. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 13 Aug 2025 | US$550.7b | US$144.1b | US$14.4b | 29.7x | 38.3x | 3.8x |
| Fri, 11 Jul 2025 | US$541.8b | US$142.9b | US$9.1b | 37.2x | 59.3x | 3.8x |
| Sun, 08 Jun 2025 | US$518.0b | US$142.9b | US$9.2b | 35.6x | 56.5x | 3.6x |
| Tue, 06 May 2025 | US$524.0b | US$142.4b | US$9.7b | 37.5x | 54.3x | 3.7x |
| Thu, 03 Apr 2025 | US$558.3b | US$142.5b | US$10.0b | 37.6x | 55.9x | 3.9x |
| Sat, 01 Mar 2025 | US$599.5b | US$143.3b | US$9.7b | 38.1x | 61.7x | 4.2x |
| Mon, 27 Jan 2025 | US$700.4b | US$142.4b | US$10.2b | 45.1x | 68.6x | 4.9x |
| Wed, 25 Dec 2024 | US$658.4b | US$142.4b | US$10.2b | 44.7x | 64.4x | 4.6x |
| Fri, 22 Nov 2024 | US$644.5b | US$142.4b | US$10.4b | 43.8x | 62.2x | 4.5x |
| Sun, 20 Oct 2024 | US$736.4b | US$141.8b | US$8.5b | 37.2x | 86.7x | 5.2x |
| Tue, 17 Sep 2024 | US$740.7b | US$141.8b | US$8.5b | 37.7x | 87.1x | 5.2x |
| Thu, 15 Aug 2024 | US$733.6b | US$141.5b | US$8.4b | 38.6x | 87.8x | 5.2x |
| Sat, 13 Jul 2024 | US$681.6b | US$141.2b | US$12.2b | 40.7x | 55.8x | 4.8x |
| Mon, 10 Jun 2024 | US$713.3b | US$141.3b | US$12.2b | 37.7x | 58.6x | 5x |
| Wed, 08 May 2024 | US$715.6b | US$141.6b | US$12.5b | 39.8x | 57.4x | 5.1x |
| Fri, 05 Apr 2024 | US$727.9b | US$142.1b | US$12.8b | 42.7x | 56.9x | 5.1x |
| Sun, 03 Mar 2024 | US$744.0b | US$142.2b | US$12.8b | 44.2x | 58.1x | 5.2x |
| Tue, 30 Jan 2024 | US$698.4b | US$153.8b | US$14.2b | 36x | 49.3x | 4.5x |
| Thu, 28 Dec 2023 | US$704.7b | US$153.8b | US$14.2b | 37.9x | 49.5x | 4.6x |
| Sat, 25 Nov 2023 | US$642.8b | US$153.8b | US$14.0b | 34.7x | 45.9x | 4.2x |
| Mon, 23 Oct 2023 | US$607.7b | US$154.6b | US$11.2b | 31.3x | 54.2x | 3.9x |
| Wed, 20 Sep 2023 | US$688.0b | US$154.6b | US$11.2b | 32.3x | 61.4x | 4.5x |
| Fri, 18 Aug 2023 | US$708.0b | US$154.6b | US$11.2b | 32.5x | 63.2x | 4.6x |
| Sun, 16 Jul 2023 | US$706.2b | US$155.5b | US$12.7b | 29.3x | 55.7x | 4.5x |
| Tue, 13 Jun 2023 | US$692.4b | US$152.4b | US$12.5b | 29.3x | 55.4x | 4.5x |
| Thu, 11 May 2023 | US$685.9b | US$152.3b | US$12.7b | 30x | 53.9x | 4.5x |
| Sat, 08 Apr 2023 | US$720.1b | US$154.6b | US$10.8b | 26.7x | 66.7x | 4.7x |
| Mon, 06 Mar 2023 | US$739.7b | US$154.5b | US$10.9b | 31x | 68x | 4.8x |
| Wed, 01 Feb 2023 | US$755.3b | US$155.5b | US$9.0b | 30.7x | 84x | 4.9x |
| Fri, 30 Dec 2022 | US$761.4b | US$155.2b | US$8.8b | 29.4x | 86.8x | 4.9x |
| Sun, 27 Nov 2022 | US$767.3b | US$155.1b | US$8.8b | 28.6x | 87.3x | 4.9x |
| Tue, 25 Oct 2022 | US$691.5b | US$152.9b | US$17.4b | 24.8x | 39.6x | 4.5x |
| Thu, 22 Sep 2022 | US$727.7b | US$152.2b | US$17.3b | 26.4x | 42x | 4.8x |
| Sat, 20 Aug 2022 | US$817.8b | US$152.3b | US$17.3b | 31.1x | 47.2x | 5.4x |
Price to Earnings Ratio
47.2x
Current Industry PE
- Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 38.3x which is lower than its 3-year average PE of 62.0x.
- The 3-year average PS ratio of 4.6x is higher than the industry's current PS ratio of 3.8x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 6.0% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 2.21% | |
| Healthcare | -0.76% | |
| Life Sciences | 2.40% | |
| Clinical Research and Equipment | 2.40% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| DHR Danaher | US$205.72 | 3.4% +US$4.8b | -23.4% | PE43.2x | |
| TMO Thermo Fisher Scientific | US$477.41 | 2.4% +US$4.1b | -21.0% | PE27.4x | |
| TEM Tempus AI | US$66.34 | 14.9% +US$1.5b | 55.5% | PS12.1x | |
| SHC Sotera Health | US$14.86 | 32.8% +US$1.0b | -0.5% | PE176.1x | |
| MTD Mettler-Toledo International | US$1.29k | 3.9% +US$1.0b | -9.0% | PE32.1x |
